Welcome to our dedicated page for Sanara Medtech news (Ticker: SMTI), a resource for investors and traders seeking the latest updates and insights on Sanara Medtech stock.
Sanara MedTech Inc. (Nasdaq: SMTI) is a medical technology company that regularly issues news and updates about its surgical, chronic wound and skin-focused business. Company announcements describe a portfolio of surgical tissue repair and advanced wound care products, including CellerateRX® Surgical Activated Collagen® Powder, BIASURGE® Advanced Surgical Solution, FORTIFY TRG® Tissue Repair Graft, FORTIFY FLOWABLE® Extracellular Matrix and several biologic bone and soft tissue matrices.
News releases often cover developments in Sanara’s commercial strategy and product adoption. For example, the company has reported on growth in soft tissue repair product sales driven by increased demand for CellerateRX Surgical and BIASURGE, expansion into additional medical facilities and the development of an independent distribution network in U.S. markets. Updates also include information on contracts and partnerships, such as an Innovative Technology contract from Vizient® Inc. for BIASURGE, which provides Vizient’s healthcare facility customers with access to the product at contracted pricing and pre-negotiated terms.
Sanara’s news flow includes financial result announcements, where it discusses segment performance, revenue trends and the impact of its strategic realignment. The company has reported the discontinuation of its Tissue Health Plus (THP) operations and the classification of THP as discontinued operations, emphasizing a renewed focus on its core surgical business. Management commentary in these releases outlines priorities related to operating efficiency and capital allocation toward surgical products.
In addition, Sanara issues updates on its product pipeline and alliances, such as its exclusive U.S. license and distribution agreement for OsStic™ Synthetic Injectable Structural Bio-Adhesive and related internal fixation technology. Investors and observers can use the SMTI news page to follow product-related announcements, financial disclosures, strategic decisions and conference participation updates that the company provides through press releases.
Sanara MedTech Inc. (NASDAQ: SMTI) reported a 42% revenue increase in Q1 2021, generating $5,009,436 compared to $3,524,331 in Q1 2020. Despite a January sales slowdown due to COVID-19, the company rebounded with record sales in March, exceeding $2 million for the first time. Notable highlights include the successful closing of a $29 million public offering, expansion of surgical product approvals to over 850 facilities, and a 23% growth in chronic wound care product sales. The net loss improved to $1,183,376 from $1,841,012 a year prior.
Sanara MedTech Inc. (NASDAQ:SMTI) announced strong financial results for the fourth quarter and full year ended December 31, 2020. The company reported a 32% increase in annual revenues to $15.6 million, with a record Q4 sales of $4.79 million, up 43% year-over-year. Despite challenges from COVID-19, Sanara expanded its product distribution and launched new products like the BIAKŌS™ Antimicrobial Wound Gel. The company also completed a public offering raising $31.6 million to fund further growth, although it reported a net loss of $4.45 million for the year.
Sanara MedTech Inc. (NASDAQ:SMTI) has successfully closed an underwritten public offering of 1,265,000 shares at $25.00 each, raising gross proceeds of $31.6 million. The offering included 165,000 additional shares exercised by underwriters. Proceeds will be used to expand the salesforce, develop product pipelines, and cover general corporate expenses. Previously, a shelf registration was filed with the SEC, and relevant prospectuses are available. Sanara aims to enhance patient outcomes through advanced wound care solutions.
Sanara MedTech Inc. has announced an underwritten public offering of 1,100,000 shares of common stock at a price of $25.00 per share, aiming for total gross proceeds of $27.5 million. The offering includes a 30-day option for underwriters to purchase an additional 165,000 shares. The offering is projected to close on February 17, 2021. Cantor Fitzgerald & Co. is the book-running manager for the offering, and the shares will be offered per an effective registration statement with the SEC.
Sanara MedTech Inc. (NASDAQ:SMTI) announced a proposed public offering of its common stock, with underwriters granted a 30-day option to purchase an additional 15% of shares. The offering is subject to market conditions and the final size and terms are yet to be determined. Cantor Fitzgerald & Co. is the book-running manager. The offering aims to improve patient outcomes through advanced wound and skin care products. Further details will be available via a prospectus filed with the SEC.
Sanara MedTech Inc. (NASDAQ: SMTI) reported preliminary results for Q4 and full year 2020, revealing Q4 revenue of $4.8 million, up 43% year-over-year from $3.4 million. Full-year revenue reached $15.6 million, a 32% increase from $11.8 million in 2019, driven by growth in sales force and distribution network expansion. Despite challenges posed by COVID-19, the company demonstrated resilience. As of December 31, 2020, cash and cash equivalents were approximately $0.5 million. Sanara also secured a $2.5 million revolving line of credit on January 15, 2021.
Sanara MedTech Inc. announced the appointment of Sara Ortwein to its Board of Directors, effective December 18, 2020. Ortwein, a former president of XTO Energy at ExxonMobil, brings 38 years of experience in engineering and management. Her addition is expected to enhance Sanara's strategic approach to wound and skin care products. Executive Chairman Ron Nixon emphasized her diversity of thought and executive-level expertise as valuable assets for the company. Sanara focuses on improving patient outcomes through advanced wound care and is expanding its telemedicine capabilities.
Sanara MedTech Inc. (NASDAQ: SMTI) reported a record revenue of $4.3 million for Q3 2020, marking a 48% increase year-over-year. The growth is attributed to the rebound in elective surgeries post-COVID restrictions. The company expanded its wound care strategy by forming United Wound and Skin Solutions LLC and investing in Direct Dermatology Inc. and Woundyne Medical LLC. Despite the revenue growth, Sanara incurred a net loss of $1.2 million for the quarter due to increased selling and administrative expenses.
Sanara MedTech Inc. (NASDAQ: SMTI) has announced an exclusive affiliation with Precision Healing, Inc. to commercialize advanced diagnostic systems aimed at enhancing chronic wound care outcomes. This partnership will utilize bedside diagnostic technology, including advanced imaging and molecular assays, to evaluate wound healing conditions. Sanara expects this innovative technology, which complements their existing wound care services and telemedicine platform, to be available commercially in 2021, contributing to their mission of improving patient outcomes through effective, evidence-based solutions.
Sanara MedTech Inc. (NASDAQ:SMTI) announced the launch of its BIAKŌS™ Antimicrobial Wound Gel and shared viral testing results for its BIAKŌS™ Skin and Wound Cleanser. The gel is designed for various wound types, promoting healing and disrupting biofilm microbes. Recent lab tests indicate that the cleanser effectively reduces SARS-CoV-2 viral loads, suggesting potential protective benefits. The Company aims to enhance patient outcomes with these products and is committed to expanding its offerings in wound care.